Experts will discuss the future of precision medicine in oncology at the end of April in Brno

Personalization of treatment in oncology, accessibility for patients and the future of precision medicine and the possibility of increasing its availability, but also possible pitfalls, all of these topics will be discussed at eighth conference of the PharmAround Foundation. After a long pause caused by the covid-19 pandemic, medical experts, the Ministry of Health, insurance companies and other stakeholders will meet again at the Courtyard by Marriot Hotel in Brno on April 27, 2022.

There is a growing attention toward personalized medicine as it brings a number of positive results, but also a number of issues and obstacles that need to be described and removed. With its concept of personalized treatment in oncology, it calls for innovative approaches that can improve and refine the treatment of many diseases. The conference will address this topic in the form of lectures and panel discussions, in 2 blocks.

The first block will focus on the specialized issues of personalized pharmacotherapy in solid oncology with the introduction of the GENESIS platform for multicenter national collaboration of “molecular tumor boards” and other ways to improve the efficacy and accuracy of personalized treatment and thus provide better outcomes for patients.

The second block will discuss current and future challenges of implementing the principles of precision medicine in oncology. The right treatment, which gets to the right patient at the right time, is a challenge that needs to be seen in terms of regulation, legislation and reimbursement. Experts from the Ministry of Health, insurance companies, SÚKL, industry representatives, clinics and academics will all share their views.

The conference is organized by the PharmAround Foundation in cooperation with the Institute of Pharmacology of the Faculty of Medicine of Masaryk University in Brno, the CZECRIN research infrastructure and the Masaryk Memorial Cancer Institute. It is intended for physicians, pharmacists, nurses, representatives of the pharmaceutical industry, academic and other professionals in the field of clinical trials, pharmacotherapy, HTA and clinical pharmacology, patients and representatives of patient organizations. For registration and general information, visit